ライフサイエンスコーパス: immunohistochemistry

1 idermal growth factor receptor positivity by immunohistochemistry).

2 nce of tau368 in tangles was evaluated using immunohistochemistry.

3 hology and vascularization were evaluated by immunohistochemistry.

4 ) of adenocarcinoma/adenosquamous cancers on immunohistochemistry.

5 ed with acetylcholinesterase and parvalbumin immunohistochemistry.

6 were collected and analyzed by histology and immunohistochemistry.

7 ription PCR, single cell RNA sequencing, and immunohistochemistry.

8 ly used in fixed cell immunofluorescence and immunohistochemistry.

9 yzed before and after eradication therapy by immunohistochemistry.

10 h a loss of H3K4 mono- and trimethylation by immunohistochemistry.

11 ed RGS4 expression in human lung biopsies by immunohistochemistry.

12 mens from CTEPH patients were analyzed using immunohistochemistry.

13 immunosorbent assay (ELISA), histology, and immunohistochemistry.

14 dendritic cell subsets, were examined using immunohistochemistry.

15 and T follicular helper were assessed using immunohistochemistry.

16 l responses after LAIV by flow cytometry and immunohistochemistry.

17 ery in Hong Kong and analyzed the tissues by immunohistochemistry.

18 or descending artery, a finding confirmed by immunohistochemistry.

19 r mitochondrial inner membrane polarity, and immunohistochemistry.

20 s, the results of which were corroborated by immunohistochemistry.

21 roteins by flow cytometry, Western blot, and immunohistochemistry.

22 r spinal cords were processed for histo- and immunohistochemistry.

23 expression of RAS enzymes was determined by immunohistochemistry.

24 istribution and fibrosis were followed using immunohistochemistry.

25 uracils, UdgX, for mammalian expression and immunohistochemistry.

26 erresolution and whole-brain imaging without immunohistochemistry.

27 aracterised by its unique histopathology and immunohistochemistry.

28 ndance of DNA-damaged nuclei using gammaH2AX immunohistochemistry.

29 A-ALCL, as indicated by phosphorylated STAT3 immunohistochemistry.

30 rlo method and experimentally validated with immunohistochemistry.

31 ignificant increase in protein expression by immunohistochemistry.

32 ers were collected from mice and analyzed by immunohistochemistry.

33 assessed by western blot and localization by immunohistochemistry.

34 d network analysis, real-time PCR (qPCR) and immunohistochemistry.

35 tive (PV(+)) interneurons were quantified by immunohistochemistry.

36 sensitive fluorescent dye extravasation and immunohistochemistry.

37 cocultured with fibroblasts, and analyzed by immunohistochemistry.

38 EWS-WT1 knockdown using JN-DSRCT-1 cells and immunohistochemistry.

39 r airway were analyzed by flow cytometry and immunohistochemistry.

40 branes were studied using RNA microarray and immunohistochemistry.

41 , with immune cell composition confirmed via immunohistochemistry.

42 population-counter package and compared with immunohistochemistry.

43 n whole mount specimens of colonic plexus by immunohistochemistry.

44 eal photography, IVCM, light microscopy, and immunohistochemistry.

45 emcitabine chemotherapy and analyzed them by immunohistochemistry.

46 tative polymerase chain reaction (qPCR), and immunohistochemistry.

47 low-passage cell lines were characterized by immunohistochemistry (22 different antibodies), array-ba

48 issue types screened for hFcRn expression by immunohistochemistry (310 samples) exhibited significant

49 MALDI-FTICR mass spectrometry, immunohistochemistry, 3D confocal microscopy, and flow c

50 Immunohistochemistry also revealed a positive and statis

51 Specimens with dMMR were identified by immunohistochemistry analyses of tissue microarrays for

52 Immunohistochemistry analysis in human prostate cancer s

53 Using immunohistochemistry and confocal microscopy, we evaluat

54 r triple expressor status were determined by immunohistochemistry and double or triple hit status was

55 mmatory cytokine expression were analysed by immunohistochemistry and electrochemiluminescent-based i

56 tsynaptic localization of SR and d-serine by immunohistochemistry and electron microscopy in mouse CA

57 same tumors were stained for aromatase using immunohistochemistry and evaluated for stain intensity a

58 Immune cell infiltrate was evaluated by immunohistochemistry and flow cytometry.

59 to be a powerful reagent for C3 detection in immunohistochemistry and flow cytometry.

60 Immunohistochemistry and flow-cytometry were used to det

61 s that are activated during Ctx-IF with cFos immunohistochemistry and found that the insular cortex,

62 response, with subsequent samples taken for immunohistochemistry and gene expression analysis.

63 s were measured in endobronchial biopsies by immunohistochemistry and gene expression.

64 therosclerotic lesions as determined by both immunohistochemistry and highly sensitive LC-MS.

65 IP(3)R-type 1) and of phosphorylated CaMKII (immunohistochemistry and immunoblot) while decreasing th

66 ion and measured levels of CXCR3 and CCR7 by immunohistochemistry and immunoblotting.

67 d in the sockets with MaR1 application under immunohistochemistry and immunofluorescence analysis.

68 l sections of frozen tissues were stained by immunohistochemistry and immunofluorescence for immune c

69 Immunohistochemistry and in situ hybridisation technique

70 We used multiplexed fluorescent immunohistochemistry and in situ hybridization in combin

71 ressing cells in the CNS, using double-label immunohistochemistry and in situ hybridization.

72 rotonergic phenotype were investigated using immunohistochemistry and in situ hybridization.

73 in the sera by ELISA and in skin biopsies by immunohistochemistry and in situ RNA hybridization.

74 ponsible for SS1P removal were identified by immunohistochemistry and intravital two-photon microscop

75 Here, by using immunohistochemistry and live-cell imaging of specific m

76 eased in human OA cartilage as determined by immunohistochemistry and microarray analysis.

77 7) to investigate changes of the metabolome, immunohistochemistry and protein levels.

78 eks post-stroke and tissue was collected for immunohistochemistry and protein quantification.

79 sion of our findings to primary HL tissue by immunohistochemistry and proximity ligation assays showe

80 rificed at E19.5 for placenta assessment via immunohistochemistry and qPCR.

81 nta, uterus, ovary, and brain of foetuses by immunohistochemistry and quantified by real-time qRT-PCR

82 In this study, we combined traditional immunohistochemistry and real-time fluorescent imaging a

83 genome, RNA, and T-cell receptor sequencing, immunohistochemistry and reverse phase protein array pro

84 y epithelial cell recovery based on napsin A immunohistochemistry and RNA expression of surfactant an

85 Immunohistochemistry and RNA sequencing were used to inv

86 sporters MCT1 and MCT4 were quantified using immunohistochemistry and RNA sequencing.

87 = 9) and brushings (n = 34 versus n = 20) by immunohistochemistry and RNA-Seq.

88 duction pathway constituents, congruent with immunohistochemistry and studies of other echinoderms [1

89 scaffolds were characterised histologically, immunohistochemistry and the residual DNA content quanti

90 Immunohistochemistry and transmission electron microscop

91 ntibody levels were quantified via ELISA and immunohistochemistry and were correlated with disease se

92 As shown by immunohistochemistry and Western blotting, PPARalpha was

93 IDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing.

94 ta were collected and analyzed by histology, immunohistochemistry, and (single-cell) RNA sequencing;

95 ical validation used an orthogonal platform, immunohistochemistry, and a larger cohort of 73 glioblas

96 diagnosis is established by histopathology, immunohistochemistry, and a systemic survey to exclude s

97 blot, enzyme-linked immunosorbent assay and immunohistochemistry, and associated with in situ comple

98 at primary neuron model, time-lapse imaging, immunohistochemistry, and confocal microscopy, we found

99 (18)F-FAC PET, digital autoradiography, and immunohistochemistry, and deoxyribonucleoside salvage ac

100 Immunoblotting, immunohistochemistry, and enzyme treatments confirmed th

101 Using enzyme-linked immunosorbent assay, immunohistochemistry, and ex vivo stimulation of brain t

102 n after MI by echocardiography, quantitative immunohistochemistry, and flow cytometry.

103 es were collected and analyzed by histology, immunohistochemistry, and flow cytometry.

104 polymerase chain reaction, Western blotting, immunohistochemistry, and fluorometric assays.

105 a standardized scale, by histopathology and immunohistochemistry, and for inflammatory protein expre

106 llected from mice and analyzed by histology, immunohistochemistry, and immunoblots.

107 althy skin by quantitative real-time PCR and immunohistochemistry, and in blood by using the OLINK pr

108 s (LMMP) tissues were collected, analyzed by immunohistochemistry, and levels of nitric oxide were me

109 otting, real-time polymerase chain reaction, immunohistochemistry, and Masson trichrome staining.

110 llected from mice and analyzed by histology, immunohistochemistry, and quantitative real-time polymer

111 sory innervation by combining viral tracing, immunohistochemistry, and reporter mouse models.

112 Here, we used classical pharmacology, immunohistochemistry, and retrograde tracing to demonstr

113 Immunoblotting, immunofluorescence, immunohistochemistry, and ribonucleoprotein immunoprecip

114 , and derived their organoids, by histology, immunohistochemistry, and RNA sequencing (RNA-seq).

115 issues from mice were analyzed by histology, immunohistochemistry, and/or quantitative polymerase cha

116 ting of invasive breast cancers by validated immunohistochemistry as the standard for predicting whic

117 ive breast cancer status and PD-L1 status by immunohistochemistry at a central laboratory; an Eastern

118 Macrosteles striifrons were investigated by immunohistochemistry-based 3D imaging, whole-mount fluor

119 Focusing further on Pfn1, we performed immunohistochemistry-based classification of Pfn1 staini

120 (3D) two-photon calcium imaging coupled with immunohistochemistry-based molecular identification to r

121 RNA-sequencing and ChIP-sequencing analyses, immunohistochemistry-based tissue microarrays, and vario

122 162 NHP were YFV positive by RT-qPCR and/or immunohistochemistry, being 22 Callithrix-spp. most from

123 apable of detecting their target antigens by immunohistochemistry but not by Western blot.

124 Immunohistochemistry confirmed enhanced CD8(+) T cell in

125 qPCR and immunohistochemistry confirmed gene and protein expressi

126 Immunohistochemistry, confocal and immunoelectron micros

127 oped a method that combines tissue clearing, immunohistochemistry, confocal microscopy, and quantitat

128 Immunohistochemistry demonstrated an increase in CD209a-

129 Autoradiography and immunohistochemistry demonstrated colocalization of [(89

130 Immunohistochemistry demonstrated colocalization of dopa

131 Immunohistochemistry demonstrated positive staining for

132 Immunohistochemistry demonstrated that CES does not indu

133 Immunohistochemistry demonstrated wolframin expression i

134 ue examination was done by light microscopy, immunohistochemistry, electron microscopy, and quantitat

135 Using immunohistochemistry, epithelial and submucosal inflamma

136 Immunofluorescence and immunohistochemistry examinations demonstrated the robus

137 Flow cytometry and immunohistochemistry experiments on two independent coho

138 s) were evaluated with slit-lamp microscopy, immunohistochemistry, flow cytometry, and polymerase cha

139 and stomach tissues and performed histology, immunohistochemistry, flow cytometry, transcriptome, and

140 ase dUTP nick-end labeling (TUNEL) assay and immunohistochemistry for active caspase-3.

141 ichlid fish Astatotilapia burtoni, including immunohistochemistry for AVT, in situ hybridization for

142 Immunohistochemistry for histamine-containing axons reve

143 in human and rat pancreases were analyzed by immunohistochemistry for immune cell infiltrate composit

144 Immunohistochemistry for p53 and mismatch repair (MMR) p

145 Immunohistochemistry for pTau, APP, GFAP, and Iba1 was p

146 osis was determined via viability assays and immunohistochemistry for RIPK1 (receptor-interacting pro

147 ds (18 chronic MS, 8 healthy controls) using immunohistochemistry for synaptophysin and synapsin.

148 was measured over time and eyes accessed by immunohistochemistry for total FN and FN-EDA expression.

149 tch-clamp recordings of ependymal cells with immunohistochemistry for various connexins in the neonat

150 ion size, as revealed by in vivo imaging and immunohistochemistry from day 3 to day 14 compared with

151 BAIAP2L2 was detected by immunohistochemistry from postnatal day 2.5 (P2.5) throu

152 By immunohistochemistry, FRZB was predominantly localized t

153 up) underwent: 1) a skin biopsy for vascular immunohistochemistry, gene expression, and chemical (wat

154 Combining immunohistochemistry, histology, and synchrotron microto

155 mass spectrometry (HPLC-MS/MS) (n = 27) and immunohistochemistry (IHC) (n = 64), on four main diagno

156 s spectrometry, verified and localized using immunohistochemistry (IHC) and confocal microscopy, and

157 Immunohistochemistry (IHC) and MS measurements for PD-L1

158 results were generally in agreement with the immunohistochemistry (IHC) data but with some exceptions

159 Here, we have generated an immunohistochemistry (IHC) dataset for five major cell-t

160 Immunohistochemistry (IHC) for CTNNB1 (beta-Catenin; clo

161 N = 26) compared with control lymph nodes by immunohistochemistry (IHC) for pS6, p4EBP1, and p70S6K,

162 RNA sequencing, methylation microarray, and immunohistochemistry (IHC) on 8 pairs of non-small cell

163 The findings were further validated by immunohistochemistry (IHC) staining in endometrial tissu

164 ment, ERS is determined by pathologists from immunohistochemistry (IHC) staining of biopsied tissue f

165 We used microarray analysis and immunohistochemistry (IHC) to examine messenger RNA and

166 through RNA expression profiling as well as immunohistochemistry (IHC) to understand its underlying

167 Classifier genes were validated by Immunohistochemistry (IHC) using tissue microarray secti

168 direct fluorescence antibody (DFA) testing, immunohistochemistry (IHC), and nucleic acid amplificati

169 of nuclear factor (NF)-kappaB expression by immunohistochemistry (IHC), degree of apoptosis by the t

170 Tumours underwent MMR immunohistochemistry (IHC), microsatellite instability (

171 Diverse assays spanning from immunohistochemistry (IHC), to microarrays (protein, DNA

172 cent in situ hybridization method (FISH) and immunohistochemistry (IHC).

173 time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC).

174 ate with the same immune cells identified by immunohistochemistry (IHC).

175 ression of MLH1 or MSH2 MMR gene products by immunohistochemistry (IHC).

176 ssion levels of ER-associated proteins using immunohistochemistry (IHC).

177 In this work, we used immunohistochemistry images from the Human Protein Atlas

178 We applied this method on CD8 immunohistochemistry images of surgically excised hormon

179 ouse macrophages were analyzed by histology, immunohistochemistry, immunoblots, and quantitative poly

180 ng were analyzed by pathological evaluation, immunohistochemistry, immunoblotting, and RNA sequencing

181 stages of tumor development and analyzed by immunohistochemistry, immunoblotting, real-time polymera

182 Immunohistochemistry, immunofluorescence, 15-PGDH activi

183 tican-2 in human kidneys was demonstrated by immunohistochemistry, immunofluorescence, and electron m

184 Echocardiography, Western blotting, qPCR, immunohistochemistry, immunofluorescence, and transcript

185 by measuring cell and activation markers via immunohistochemistry, immunofluorescence, Luminex assay,

186 Immunohistochemistry/immunofluorescence for CD1a, CD3, C

187 ere analyzed centrally with NGS and selected immunohistochemistry in a master screening protocol.

188 in pancreatic cancer cells was confirmed by immunohistochemistry in a series of 99 human pancreatic

189 perivascular macrophages were identified by immunohistochemistry in brain parenchyma in over 40% of

190 n analyses in primary neuronal cultures, and immunohistochemistry in brains of wild-type and Drebrin

191 g, electrophoretic mobility-shift assay, and immunohistochemistry in liver of S. mansoni-infected ham

192 ell as liver fibrosis were evaluated by both immunohistochemistry in liver sections and real-time PCR

193 Immunohistochemistry in male and female Cx(3)cr1 (CreER/

194 sferase dUTP nick end labeling staining, and immunohistochemistry in murine cells, tissues, or retina

195 tortion product of otoacoustic emissions and immunohistochemistry in the rat show that the peripheral

196 D3, CD8 and CD68 expression was evaluated by immunohistochemistry in tumor infiltrating immune cells,

197 Using a combination of immunohistochemistry, in situ hybridization, and a trans

198 We also used immunohistochemistry, in situ hybridization, and electro

199 43(+) and PKCdelta_pY311(+)), as assessed by immunohistochemistry, indicating increased SFK activity

200 n individual fibres from a single section by immunohistochemistry is limited but imaging mass cytomet

201 them with a combination of morphological and immunohistochemistry markers.

202 r capture microdissected on the basis of MYC immunohistochemistry, MYC activity, and MEIS1 expression

203 ysed using qPCR (n = 100) and OPN protein by immunohistochemistry (n = 116) using different antibodie

204 correlated with tumor mutation burden, PD-L1 immunohistochemistry, nor T-effector gene signatures.

205 oxide synthase (eNOS) and endothelin-1; (d) immunohistochemistry of eNOS, endothelin-1, P-selectin,

206 lls, single-cell bioinformatics analysis and immunohistochemistry of lung autopsy samples revealed th

207 Immunohistochemistry of mice treated subcutaneously with

208 try of dispersed tissue fragments and serial immunohistochemistry of paraffin-embedded sections of na

209 Autoradiography and immunohistochemistry of the aorta revealed that (68)Ga-F

210 Immunohistochemistry of the pancreatic remnant revealed

211 Immunohistochemistry of transplanted lungs demonstrated

212 Immunohistochemistry on 134 estrogen receptor (ER(+)) pr

213 emerged among the top DEGs, as confirmed by immunohistochemistry on CNV tissue and protein analysis

214 Immunohistochemistry on NAcore labeled spines with ChR2-

215 Protein levels of ACE2 were visualized by immunohistochemistry on paraffin-embedded lung tissue sa

216 We performed anatomical tracing, immunohistochemistry, optogenetic (GCaMP calcium imaging

217 by both CD3 and CD8 lymphocytes measured via immunohistochemistry (p < 001, p < 0.001 respectively).

218 were higher in HER3-EGFR-high TNBCs based on immunohistochemistry (p = 0.036).

219 After central confirmation of TNBC status by immunohistochemistry, patients were randomly assigned to

220 By immunohistochemistry, PCSK6 was localized to fibrous cap

221 Immunohistochemistry performed using double labeling tec

222 side 37 stable controls, were analyzed using immunohistochemistry, polychromatic flow cytometry, and

223 regates was confirmed using a combination of immunohistochemistry, quantitative polymerase chain reac

224 ther analysis was performed by Western blot, immunohistochemistry, real-time polymerase chain reactio

225 evaluated in 147 primary cervical tumors by immunohistochemistry, real-time polymerase chain reactio

226 sing two clinically validated antibodies for immunohistochemistry respectively were highly correlated

227 -bMPOKO mice was confirmed by immunoblot and immunohistochemistry, respectively.

228 tions than in healthy controls, in line with immunohistochemistry results.

229 iferase expression in AAV8-NFkappaB mice and immunohistochemistry revealed GFP expression in cells of

230 Immunohistochemistry revealed more directional nerve fib

231 PSMA immunohistochemistry revealed strong PSMA staining of be

232 Immunohistochemistry revealed that CCR2i-treated tumors

233 Immunohistochemistry revealed that OASIS protein was ove

234 Immunohistochemistry reveals that PAL/HCQ co-delivery na

235 al validation of variants was carried out by immunohistochemistry, reverse-transcriptase polymerase c

236 grade biomarkers (blood/tissue NGS, specific immunohistochemistry/RNA expression including for immune

237 Furthermore, histologic analysis, immunohistochemistry, RNAscope in situ hybridization, an

238 By immunohistochemistry, RNAscope in situ hybridization, tr

239 ICAM1 immunohistochemistry showed enrichment in brain endothel

240 istently highly expressed in angiomyolipoma, immunohistochemistry showed microphthalmia-associated tr

241 SARS-CoV-2 immunohistochemistry showed nonspecific staining, wherea

242 Immunohistochemistry showed significant decreases in mar

243 on CSF tracer injection in combination with immunohistochemistry showed that chronically implanted e

244 Immunohistochemistry showed that GT3-Nano accumulates in

245 Immunohistochemistry showed that most of the COX2 was in

246 Immunohistochemistry showed that NPFFR2, syncytin 1/2, a

247 thms can extract precise cell locations from immunohistochemistry slides, but the resulting spatial c

248 alidation techniques used include histology, immunohistochemistry, spectrometry and spectroscopy.

249 in ampullary adenocarcinoma was detected by immunohistochemistry staining and correlated with patien

250 MRI using diffusion-tensor imaging (DTI) and immunohistochemistry staining of the brain and eyes.

251 An immunohistochemistry study showed that p-ERK and RelB we

252 onal lymph node metastases were evident, and immunohistochemistry supported a neuroendocrine origin.

253 We show by immunohistochemistry that, in del10 homozygotes, neural

254 in O3-exposed KKAy lungs was confirmed with immunohistochemistry, tissue hydroxyproline content, and

255 Eleven immune markers were studied using immunohistochemistry, tissue microarray, and digital ima

256 Finally, we used immunohistochemistry to analyze protein levels of vGAT a

257 2+)-imaging to monitor PSC activity and used immunohistochemistry to analyze their repair and phagocy

258 tilize RNA-sequencing, CyTOF and correlative immunohistochemistry to assess immune-profiles in these

259 ed tumors and analyzed them by histology and immunohistochemistry to assess neural remodeling.

260 d by Western blotting, quantitative PCR, and immunohistochemistry to assess YY1, TH, GLAST, and GLT-1

261 n X-ray fluorescence imaging, histology, and immunohistochemistry to compare the iron quantity and di

262 Human and mouse corneas were subjected to immunohistochemistry to detect wolframin expression and

263 nt cell lines, gene expression analyses, and immunohistochemistry to evaluate a series of first-in-cl

264 al changes in hippocampal subfields and cFos immunohistochemistry to examine cellular excitability.

265 This study utilised cell sorting and immunohistochemistry to identify a phenotypically-distin

266 Using immunohistochemistry to label microglia, we performed mo

267 We employed immunohistochemistry to map dopaminergic innervation, an

268 In this study, we used fluorescent immunohistochemistry to map their expression patterns th

269 g, combined with spatial transcriptomics and immunohistochemistry, to comprehensively characterize su

270 dimensional counterparts, flow cytometry and immunohistochemistry, to meet this need.

271 bination of scanning electron microscopy and immunohistochemistry together with phalloidin labeling,

272 Viral detection encompassed SARS-CoV-2 immunohistochemistry, ultrastructural examination, and d

273 Immunohistochemistry using astrocytic (glial fibrillary

274 We performed immunohistochemistry using retinas from Bardet-Biedl Syn

275 Using immunohistochemistry-validated computational tools that

276 qPCR and immunohistochemistry verified the significant upregulati

277 ivation of the dentate gyrus (DG) using cFos immunohistochemistry was measured as a negative control

278 ylin and eosin and Perls' Prussian blue, and immunohistochemistry was performed against amyloid-beta

279 Histopathology was re-assessed, and expanded immunohistochemistry was performed from tissue specimens

280 Immunohistochemistry was performed to determine the regi

281 Immunohistochemistry was performed to examine colocaliza

282 Multiplexed immunohistochemistry was used to analyze expression and

283 Immunohistochemistry was used to characterize S aureus u

284 sing lymphatic reporter mice and whole mount immunohistochemistry was used to evaluate the lymphatic

285 f transcriptomics, in situ hybridization and immunohistochemistry we find evidence for the expression

286 pment of therapeutics.METHODSUsing multiplex immunohistochemistry, we characterized cerebrovascular i

287 ing long-term EdU incorporation analysis and immunohistochemistry, we found that bronchiolar cell den

288 Through immunohistochemistry, we found that the lining synovial

289 itation, mass spectrometry, Western blot and immunohistochemistry, we found that the target antigens

290 Using immunohistochemistry, we identified 44 structures that s

291 Lastly, using immunohistochemistry, we observed an overall decrease in

292 Using immunohistochemistry, we performed tau phenotyping of CT

293 Analyzing 453 consecutive RCC tumors by immunohistochemistry, weakly negative, but significant c

294 Histology and immunohistochemistry were performed in pancreatic specim

295 Flow cytometry and immunohistochemistry were used to assess engraftment and

296 Invasive electrophysiological, immunohistochemistry, Western blotting, and patch clampi

297 Samples were analyzed by histology, immunohistochemistry, western blotting, and polymerase c

298 ed by different experimental methods such as immunohistochemistry, western-blotting, and also by enzy

299 uminal (GATA3) and basal (KRT5/6) markers by immunohistochemistry, which identified molecular subtype

300 as transferred onto a glass slide to perform immunohistochemistry with H&E counterstaining for cell i